<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Despite variable clinical results, beta blockers have become the primary therapy for prevention of <z:mp ids='MP_0010574'>aortic dilation</z:mp> in patients with the <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>This study examines the use of the <z:chebi fb="0" ids="35457">angiotensin-converting enzyme inhibitor</z:chebi> enalapril for treatment of these patients </plain></SENT>
<SENT sid="2" pm="."><plain>We sought to examine the effects of enalapril versus beta-blocker therapy in patients with the <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> and noted improved aortic distensibility (3.0 +/- 0.3 vs 1.9 +/- 0.4 cm2 dynes(-1); p &lt;0.02) and a reduced aortic stiffness index (8.0 +/- 2.9 vs 18.4 +/- 3.8; p &lt;0.05) in patients receiving enalapril compared with those receiving beta blockers </plain></SENT>
<SENT sid="3" pm="."><plain>These favorable hemodynamic changes were associated with a smaller increase in aortic root diameter (0.1 +/- 1.0 vs 5.8 +/- 5.2 mm) and fewer clinical end points during follow-up </plain></SENT>
</text></document>